Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Vaccine design: emerging concepts and renewed optimism.

Grimm SK, Ackerman ME.

Curr Opin Biotechnol. 2013 Dec;24(6):1078-88. doi: 10.1016/j.copbio.2013.02.015. Epub 2013 Mar 7. Review.

2.

Principles of Vaccination.

Zepp F.

Methods Mol Biol. 2016;1403:57-84. doi: 10.1007/978-1-4939-3387-7_3.

PMID:
27076125
3.

Vaccine platforms combining circumsporozoite protein and potent immune modulators, rEA or EAT-2, paradoxically result in opposing immune responses.

Schuldt NJ, Aldhamen YA, Appledorn DM, Seregin SS, Kousa Y, Godbehere S, Amalfitano A.

PLoS One. 2011;6(8):e24147. doi: 10.1371/journal.pone.0024147. Epub 2011 Aug 30.

4.

Jump-starting the immune system: prime-boosting comes of age.

Woodland DL.

Trends Immunol. 2004 Feb;25(2):98-104. Review.

PMID:
15102369
5.
6.
7.

Molecular vaccines for malaria.

Bruder JT, Angov E, Limbach KJ, Richie TL.

Hum Vaccin. 2010 Jan;6(1):54-77. Epub 2010 Jan 29. Review.

PMID:
20061792
8.

A 2020 vision for vaccines against HIV, tuberculosis and malaria.

Rappuoli R, Aderem A.

Nature. 2011 May 26;473(7348):463-9. doi: 10.1038/nature10124.

PMID:
21614073
9.

Measuring the Adjuvant Activity of RNA Vaccines.

Pardi N, Weissman D.

Methods Mol Biol. 2017;1499:143-153.

PMID:
27987147
10.

Molecular signatures of vaccine adjuvants.

Olafsdottir T, Lindqvist M, Harandi AM.

Vaccine. 2015 Sep 29;33(40):5302-7. doi: 10.1016/j.vaccine.2015.04.099. Epub 2015 May 16. Review.

11.

DNA vaccines: a review.

Lewis PJ, Babiuk LA.

Adv Virus Res. 1999;54:129-88. Review.

PMID:
10547676
12.

Recent developments in adjuvants for vaccines against infectious diseases.

O'Hagan DT, MacKichan ML, Singh M.

Biomol Eng. 2001 Oct 15;18(3):69-85. Review.

PMID:
11566599
13.

Molecular adjuvants for malaria DNA vaccines based on the modulation of host-cell apoptosis.

Bergmann-Leitner ES, Leitner WW, Duncan EH, Savranskaya T, Angov E.

Vaccine. 2009 Sep 18;27(41):5700-8. doi: 10.1016/j.vaccine.2009.06.059. Epub 2009 Jul 2.

PMID:
19576940
14.

Immunity in response to particulate antigen-delivery systems.

Storni T, K√ľndig TM, Senti G, Johansen P.

Adv Drug Deliv Rev. 2005 Jan 10;57(3):333-55. Review.

PMID:
15560945
15.

Enhanced non-inflammasome mediated immune responses by mannosylated zwitterionic-based cationic liposomes for HIV DNA vaccines.

Qiao C, Liu J, Yang J, Li Y, Weng J, Shao Y, Zhang X.

Biomaterials. 2016 Apr;85:1-17. doi: 10.1016/j.biomaterials.2016.01.054. Epub 2016 Jan 29.

PMID:
26851653
16.

Innate immunity and new adjuvants.

Mutwiri G, Gerdts V, Lopez M, Babiuk LA.

Rev Sci Tech. 2007 Apr;26(1):147-56. Review.

PMID:
17633299
17.

Role of adjuvants in modeling the immune response.

Carter D, Reed SG.

Curr Opin HIV AIDS. 2010 Sep;5(5):409-13. doi: 10.1097/COH.0b013e32833d2cdb. Review.

18.

Fully mobilizing host defense: building better vaccines.

Raychaudhuri S, Rock KL.

Nat Biotechnol. 1998 Nov;16(11):1025-31. Review.

PMID:
9831030
19.

Soluble multi-trimeric TNF superfamily ligand adjuvants enhance immune responses to a HIV-1 Gag DNA vaccine.

Kanagavelu SK, Snarsky V, Termini JM, Gupta S, Barzee S, Wright JA, Khan WN, Kornbluth RS, Stone GW.

Vaccine. 2012 Jan 17;30(4):691-702. doi: 10.1016/j.vaccine.2011.11.088. Epub 2011 Dec 4.

20.

Synthetic Toll-like receptor agonists for the development of powerful malaria vaccines: a patent review.

Kaur A, Kannan D, Mehta SK, Singh S, Salunke DB.

Expert Opin Ther Pat. 2018 Nov;28(11):837-847. doi: 10.1080/13543776.2018.1530217. Review.

PMID:
30280939

Supplemental Content

Support Center